Essayer OR - Gratuit

Addressing Challenges in Cell Therapy Manufacturing

BioSpectrum Asia

|

BioSpectrum Asia April 2024

Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.

Addressing Challenges in Cell Therapy Manufacturing

Cancer research has come a long way. Along with technology advancements, the basic options for treating cancer, such as surgery, radiation, and chemotherapy, have expanded their mainstays when immunotherapy is developed. Individualised CAR-T cell therapy uses a patient’s immune system to fight specific types of cancers or a broad spectrum of immuno-oncology and infectious diseases. Cell-based therapies aim to treat diseases by altering or restoring certain sets of cells or using cells to carry a therapy through the body.

Despite substantial progress in this field, cell therapy manufacturing presents multiple challenges that must be addressed as production scales up. At Agilent, our cell analysis team works closely with cell therapy manufacturing companies to explore innovative technologies that can overcome some of these challenges locally, regionally, and globally.

PLUS D'HISTOIRES DE BioSpectrum Asia

BioSpectrum Asia

Leadgene Biosolutions expands product portfolio for metabolic research

Leadgene Biosolutions has announced the expansion of its product portfolio following its strategic integration into Leadgene Biomedical.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Korea, Philippines to develop nextgeneration tuberculosis diagnosis

The Korea National Institute of Health (NIH), under the Korea Disease Control and Prevention Agency (KDCA) is entering into a research agreement with the Research Institute for Tropical Medicine (RITM) of the Philippines to initiate an international collaborative research project aimed at developing next-generation tuberculosis (TB) diagnostic technologies.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Australia and Indonesia achieve WHO Listed Authority status in medical products regulation

The World Health Organization (WHO) has formally recognised the regulatory authorities for medical products of Australia and Indonesia as WHO Listed Authorities (WLAs), an achievement that underscores growing global confidence in regulatory systems across diverse regions and income settings.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries

Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Aevice Health announces expansion into Australian market

AeviceMD Monitoring System, a non-invasive wearable respiratory monitoring solution developed by Singapore-based Aevice Health, has been included in the Australian Register of Therapeutic Goods (ARTG) as a Class IIa medical device.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Insilico Medicine lists on Hong Kong Stock Exchange, exhibiting largest Hong Kong biotech IPO

Insilico Medicine, a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Australia provides cheaper medicines for inflammatory & rare liver disease and MS

Australians living with a range of debilitating conditions including juvenile arthritis, rare liver disease and multiple sclerosis (MS) will pay less for newly Pharmaceutical Benefits Scheme (PBS) listed medicines, as directed by the Australian Government.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Valneva and Serum Institute of India discontinue Chikungunya vaccine license agreement

France-based Valneva SE, a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company, have mutually agreed to discontinue their license agreement for Valneva's single-shot chikungunya vaccine.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Santhera licenses AGAMREE to Nxera Pharma in $205 M Asia-Pacific deal

Swiss firm Santhera Pharmaceuticals has signed an exclusive licensing agreement with Nxera Pharma UK for the development, manufacturing and commercialisation of AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in Japan, South Korea, Australia and New Zealand.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

AdCella and Shanghai Cell Therapy Group launch global collaboration for cancer therapy

Australia-based AdAlta, developer of next generation cell and protein therapeutic products, and its cellular immunotherapy subsidiary, AdCella have signed a major development agreement with Shanghai Cell Therapy Group (SHcell) to bring an innovative cancer treatment, BZDS1901, to markets outside China.

time to read

1 min

BioSpectrum Asia Feb 2026

Listen

Translate

Share

-
+

Change font size